US 12,324,576 B2
Flexible system for delivering an anchor
Joseph Catanese, III, Oakland, CA (US); Floria Cheng, San Francisco, CA (US); Theodore C. Lamson, Pleasanton, CA (US); Raul Macatangay, San Jose, CA (US); Matthew McLean, San Francisco, CA (US); Thomas C. Ryan, Livermore, CA (US); Ling-Kang Tong, Fremont, CA (US); and Brian Y. Tachibana, Oakland, CA (US)
Assigned to Teleflex Life Sciences LLC, Wilmington, DE (US)
Filed by Teleflex Life Sciences LLC, Wilmington, DE (US)
Filed on Mar. 10, 2023, as Appl. No. 18/181,797.
Application 18/181,797 is a continuation of application No. 17/723,826, filed on Apr. 19, 2022.
Application 17/723,826 is a continuation of application No. 16/166,312, filed on Oct. 22, 2018, granted, now 11,331,093, issued on May 17, 2022.
Application 16/166,312 is a continuation of application No. 13/538,758, filed on Jun. 29, 2012, granted, now 10,130,353, issued on Nov. 20, 2018.
Prior Publication US 2023/0200802 A1, Jun. 29, 2023
Int. Cl. A61B 17/04 (2006.01); A61B 1/00 (2006.01); A61B 17/00 (2006.01); A61B 17/02 (2006.01); A61B 17/06 (2006.01); A61B 17/064 (2006.01); A61B 90/00 (2016.01)
CPC A61B 17/0401 (2013.01) [A61B 1/00148 (2022.02); A61B 1/00183 (2013.01); A61B 17/0644 (2013.01); A61B 2017/00274 (2013.01); A61B 2017/003 (2013.01); A61B 2017/00309 (2013.01); A61B 2017/00314 (2013.01); A61B 2017/00323 (2013.01); A61B 2017/00557 (2013.01); A61B 2017/00867 (2013.01); A61B 2017/00871 (2013.01); A61B 2017/00893 (2013.01); A61B 2017/00964 (2013.01); A61B 17/0218 (2013.01); A61B 2017/0409 (2013.01); A61B 2017/0419 (2013.01); A61B 2017/0464 (2013.01); A61B 2017/06052 (2013.01); A61B 2017/0641 (2013.01); A61B 2017/0645 (2013.01); A61B 2017/0649 (2013.01); A61B 2090/037 (2016.02)] 20 Claims
OG exemplary drawing
 
1. A method for treating benign prostatic hyperplasia, comprising:
inserting a tubular elongate device longitudinally through a urethra of a subject until at least a distal portion of the tubular elongate device reaches a prostatic urethra and a bladder, where the distal portion of the tubular elongate device is rotated while within an interior portion of the bladder;
advancing a needle from the distal portion of the tubular elongate device through a prostatic capsule and into a prostate gland that has a size, wherein advancing the needle through the prostatic capsule and into the prostate gland is a step in reducing the size of the prostate gland, wherein the needle assumes a curved configuration upon being ejected from the distal portion of the tubular elongate device; and
tracking a position of the needle using an endoscopic device advanced to the prostatic urethra.